Metabolic Fatloss Peptides Cluster
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
How can it help me?
These five compounds are the fat-loss and “exercise-in-a-pill” peptides that sit outside OHM's two main metabolic lanes. AOD-9604 and HGH Fragment 176-191 are growth-hormone fragments isolated for the fat-burning part of the molecule — but both come from a lineage of human trials that came back negative. AICAR and SLU-PP-332 are exercise-mimetics studied mostly in animals. Adipotide is the outlier, and the one we flag hardest — it carries a real toxicity signal (kidney damage in primates).
Honest read: the evidence here is thin and mostly preclinical. This is reference content, not a recommendation.
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Typical dosing
Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.
What should I avoid combining — and what's synergistic?
The headline caution: Adipotide has a documented toxicity signal and isn't something to experiment with. The rest are early-stage research compounds with no established human protocol — don't stack them expecting GLP-1-level results, because that's not what the evidence shows.
How can I buy this?
We don't have a verified affiliate source for Metabolic Fatloss Peptides Cluster yet, so there's no coupon or vendor link here — we won't point you to a seller we haven't vetted. When buying any research-use-only peptide, the single biggest variable is the supply chain: insist on a vendor that publishes third-party Certificates of Analysis (COAs) confirming identity and >99% purity. Working with a peptide-literate clinician is one solid route — see our provider directory — or check back as our verified sources list grows.
Why this is a cluster article
These five compounds are the fat-loss and exercise-mimetic peptides that sit outside the two main metabolic lanes OHM already covers in depth:
- They are not GLP-1-class — they don’t touch the incretin axis the way Retatrutide (a triple GLP-1/GIP/glucagon agonist — never lump it with single GLP-1s) and the rest of the The 2026 GLP-1 pipeline — Dulaglutide, Liraglutide, Semaglutide, Tirzepatide, CagriSema, Mazdutide, MariTide, Pemvidutide, Petrelintide, VK2735, Orforglipron, Survodutide, Eloralintide, Retatrutide family do.
- They are not the mitochondrial pair — distinct from MOTS-c and SS-31 (Elamipretide), which work through mitochondrial-derived signaling and cardiolipin protection rather than direct lipolysis or AMPK/ERR activation.
Inside this cluster there are three sub-stories:
- AOD-9604 + HGH Fragment 176-191 are closely related: both are C-terminal fragments of human growth hormone (residues ~176-191) isolated for the fat-burning portion of the molecule without GH’s growth-promoting effects. AOD-9604 is the modified, stabilized version (a Tyr-added analog of the fragment); HGH Fragment 176-191 is the bare fragment. They share the same negative-Phase-2 lineage.
- AICAR + SLU-PP-332 are exercise-mimetics — “exercise in a pill” research compounds. AICAR activates AMPK; SLU-PP-332 is a pan-ERR (estrogen-related receptor) agonist. Both are small molecules, not true peptides, but the research community groups them with metabolic peptides.
- Adipotide is the outlier: a pro-apoptotic targeting peptidomimetic designed to kill the blood supply to fat tissue. It carries a real toxicity signal (primate nephrotoxicity) and is the one compound here we flag hardest.
None of the five is in Alyve’s launch catalog. This is encyclopedia/authority content — the honest map of what’s out there in fat-loss peptides beyond the GLP-1s. The commercial cross-links at the end route to the metabolic SKUs Alyve actually sells.
Quick-reference table
| Compound | Class | Mechanism | Strongest evidence | OHM grade | Honest status |
|---|---|---|---|---|---|
| AOD-9604 | Modified HGH C-terminal fragment | Claimed lipolysis ↑ / lipogenesis ↓ without GH or blood-sugar effect | Human Phase 2 conducted — failed primary weight-loss endpoint | C / green PRIMARY lose-weight | Molecule is safe; the weight-loss claim is not supported by its own RCT |
| HGH Fragment 176-191 | Bare HGH C-terminal fragment | Same lipolytic region as AOD, no disulfide stabilization | 1 in-vitro study (breast-cancer cytotoxicity model, unrelated to fat loss) | D / provisional | Same negative-Ph2 lineage as AOD; no independent human grounding |
| AICAR | AMPK activator (nucleoside analog) | Activates AMP-kinase → fat oxidation, glucose uptake, mitochondrial biogenesis | Preclinical “exercise in a pill” mouse data (Salk) | D / provisional | No human efficacy trials; WADA-banned |
| SLU-PP-332 | Pan-ERR agonist (small molecule) | ERR (estrogen-related receptor) agonism → exercise-like metabolic program | 3 preclinical studies (mouse exercise-mimetic + aging kidney) | D / provisional | Preclinical-only; no human trials |
| Adipotide | Pro-apoptotic targeting peptidomimetic | Targets prohibitin-1 on fat-tissue vasculature → cuts blood supply → fat-cell apoptosis | Preclinical primate fat-mass reduction | D / RED / provisional | Primate nephrotoxicity signal; no human trials |
AOD-9604
What it is
AOD-9604 (“Anti-Obesity Drug 9604”) is a modified C-terminal fragment of human growth hormone, corresponding to amino acids ~176-191 of the HGH molecule with a tyrosine modification for stability. It was developed by Metabolic Pharmaceuticals (Australia) specifically to isolate HGH’s fat-metabolizing activity without the growth-promoting, blood-sugar, or IGF-1 effects of the full hormone. thepeptidelist.com files it under weight-loss (secondary: growth-hormone).
How it works
Per thepeptidelist.com: an HGH fragment (amino acids 177-191) that may stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat formation) without affecting blood sugar or growth.
The appeal of the mechanism is exactly that decoupling — the fat-loss part of growth hormone without the GH-axis baggage. That’s the theory the molecule was built on. The 0035 grading notes AOD has no GH-axis effect, which is why its safety profile is benign.
What the research shows
The honest headline: AOD-9604 has real human data, and the human data is negative for weight loss.
- Phase 2 obesity trials FAILED the primary endpoint — no significant weight loss vs placebo. That failure is why the molecule lost commercial development.
- thepeptidelist.com’s own evidence summary: “Eight human studies of AOD-9604 have been conducted, with no randomized controlled trials identified.” The site grades it Emerging (10 studies cited, 0 RCTs).
- Several of the cited studies are not efficacy work at all — they are anti-doping analytical-method papers (Thevis group) examining how to detect the compound, including the finding that AOD-9604 does not trigger the WADA hGH isoform immunoassay (Orlovius et al., Drug Test Anal 2013, PMID 24124033).
- A more recent orthopedic-peptide review (Rahman, Lee, Seeds; J Am Acad Orthop Surg Glob Res Rev 2026, PMID 41490200) lists AOD among peptides examined for orthopedic application — a separate research thread from fat loss.
The honest read (per OHM doctrine: lead with the failed Phase 2): AOD-9604 is one of the rare research peptides that actually got a real human obesity trial — and the trial said it doesn’t produce significant weight loss. The molecule is widely marketed as a fat-loss peptide; its own RCT base does not back that claim. Surfacing that honestly is the authority play, not amplifying the marketing.
Real-world protocol (community / practitioner convention)
For educational purposes — this documents what the practitioner community uses, not a prescription.
AOD-9604 appears on the one practitioner cheat sheet in the non-Alyve / future-expansion list, but the specific row was not captured in our Alyve-relevant extract: the captured table covers only launch-catalog peptides. The community convention typically cited is ~300 mcg/day subcutaneous, often AM/fasted, in 8-week-on/off blocks — but treat that as forum/practitioner convention, not trial-derived, and note that the human trial that does exist was negative on the endpoint the dose is aimed at.
Status
- Regulatory: Not FDA-approved for human use. Sold as a research chemical. Per thepeptidelist.com, AOD was removed from the compounding nomination list: “HGH fragment not eligible for compounding” (status date 2024-03-21), placing it in the FDA
banned_from_compoundingcategory. - Safety: Benign profile, no GH-axis effect. OHM grade: C / green, PRIMARY lose-weight (the C-tier reflects a real human Ph2 that happened to be negative — not absence of data).
- Alyve catalog: Not in the launch 15.
HGH Fragment 176-191
What it is
HGH Fragment 176-191 is the bare lipolytic fragment of human growth hormone — the same residue region AOD-9604 is built from, but without the disulfide-bond / tyrosine modification that stabilizes AOD. Per the 0035 pass: “Same molecule body as AOD-9604 (without disulfide bond).” thepeptidelist.com files it under weight-loss.
How it works
Per thepeptidelist.com: an isolated lipolytic region of HGH that may stimulate fat breakdown without affecting blood sugar or promoting cellular growth.
Mechanistically it’s marketed identically to AOD — the fat-burning slice of growth hormone, GH effects stripped out. The difference is stabilization and, critically, evidence depth.
What the research shows
This is the thinnest evidence base in the cluster:
- thepeptidelist.com grades it Anecdotal — 1 study cited, 0 human trials.
- The single cited study isn’t even about fat loss: it’s an in-vitro breast-cancer paper — the fragment enhanced the cytotoxicity of doxorubicin-loaded chitosan nanoparticles against MCF-7 cells (Habibullah et al., Drug Des Devel Ther 2022, PMID 35783198). That tells us nothing about human fat loss.
- OHM grade: D / provisional — “Same negative-Ph2 lineage; no independent grounding.” It inherits AOD-9604’s failed-Phase-2 story without adding any human data of its own.
The honest read: HGH Fragment 176-191 is researcher-community interest with formal data that is thin. It rides on the same GH-fragment fat-loss premise as AOD-9604 — and that premise has a negative human Phase 2 behind it. Educational mention; no recommendation.
Real-world protocol
No validated protocol exists. The community treats it interchangeably with AOD-9604 (similar mcg-range SubQ, fasted-AM convention), but there is no human dose-finding study and no captured cheat-sheet row for this exact compound.
Status
- Regulatory:
research_only— not approved for human use, not eligible for compounding (per thepeptidelist.com). - OHM grade: D / provisional (kept provisional, encyclopedia-only).
- Alyve catalog: Not in the launch 15.
AICAR
What it is
AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide) is not a peptide — it’s a nucleoside analog / AMPK activator, but it’s commonly grouped with metabolic peptides in the research-compound world. It’s one of the two original “exercise in a pill” compounds, traced to Salk Institute metabolic research. thepeptidelist.com files it under weight-loss (secondary: anti-aging).
How it works
Per thepeptidelist.com: activates AMP-activated protein kinase (AMPK), a master metabolic regulator that shifts cellular metabolism toward fat oxidation, glucose uptake, and mitochondrial biogenesis.
AMPK is the cell’s low-energy sensor — when ATP runs low and AMP rises, AMPK switches the cell into “burn fuel, build mitochondria” mode, which is much of what endurance exercise does. AICAR mimics that signal pharmacologically, which is the entire “exercise mimetic” pitch.
What the research shows
- The defining work is preclinical “exercise in a pill” mouse data (Salk Institute) — sedentary mice given AICAR showed improved running endurance and an endurance-trained metabolic gene-expression signature.
- thepeptidelist.com grades it Anecdotal — 0 studies cited on the profile, 0 human trials (it points to a ClinicalTrials.gov search rather than a specific landmark).
- No human efficacy trials for fat loss or endurance.
Side effects & safety flag
- WADA-banned. AICAR is a prohibited substance in sport — the AMPK/endurance-mimetic mechanism is exactly the performance-enhancement use anti-doping authorities target. This is the headline regulatory fact for AICAR.
- No human safety database for the doses implied by the mouse work, which used large systemic exposures. Frame as preclinical-only.
Real-world protocol
No validated human protocol. AICAR is encyclopedia-only here — the mouse studies used weight-based dosing that doesn’t translate to a documented human regimen.
Status
- Regulatory:
research_only, not FDA-approved, not eligible for compounding; WADA prohibited. - OHM grade: D / provisional (encyclopedia-only).
- Alyve catalog: Not in the launch 15.
SLU-PP-332
What it is
SLU-PP-332 is a small-molecule pan-ERR (estrogen-related receptor) agonist — the second-generation “exercise pill” research compound, developed in academic metabolic-pharmacology labs (the SLU-PP series). Like AICAR, it’s not a peptide but is grouped with the metabolic cluster. thepeptidelist.com files it under weight-loss (secondary: performance). (Note: the compound is sometimes written SLU-PP-322; the canonical designation in the source studies is SLU-PP-332.)
How it works
Per thepeptidelist.com: an ERR (estrogen-related receptor) agonist that may activate exercise-like metabolic pathways and improve endurance.
The estrogen-related receptors (ERRα/β/γ) are master regulators of mitochondrial biogenesis and oxidative metabolism — the same program endurance training switches on. SLU-PP-332 activates them directly, which is why it’s pitched as an exercise mimetic distinct from the AMPK route AICAR takes.
What the research shows
This is the best-documented exercise-mimetic in the cluster, but still entirely preclinical:
- thepeptidelist.com grades it Emerging — 3 studies cited, 0 human trials.
- Billon et al., J Pharmacol Exp Ther 2026 (PMID 41421047) — an orally active ERR agonist (the related SLU-PP-915) enhanced aerobic exercise capacity in mice with exercise-mimetic activity.
- Wang et al., Am J Pathol 2023 (PMID 37717940) — ERR agonism reversed age-related kidney dysfunction, albuminuria, and inflammation in aging mice over an 8-week course (an anti-aging angle beyond fat loss).
- Möller, Krug, Thevis, Rapid Commun Mass Spectrom 2026 (PMID 41588687) — characterized the metabolites of SLU-PP-332 and SLU-PP-915 as “Novel Pan-ERR Agonists With Doping Potential” — i.e., anti-doping science is already building detection methods, the same pattern AICAR followed.
The honest read: early but genuinely interesting. A single high-profile mouse study showed exercise-mimetic fat-loss + endurance; there are no human trials. Surface it as a compound to watch, not a prescription — heavy posture.
Real-world protocol
No human protocol exists — preclinical-only.
Status
- Regulatory:
research_only, not FDA-approved, not eligible for compounding. Anti-doping detection methods already in development (doping-potential flag). - OHM grade: D / provisional (encyclopedia-only).
- Alyve catalog: Not in the launch 15.
Adipotide
What it is
Adipotide (FTPP / prohibitin-targeting peptide) is a pro-apoptotic peptidomimetic developed at MD Anderson Cancer Center. It’s mechanistically unlike everything else in this cluster: it doesn’t nudge metabolism, it’s designed to destroy fat tissue’s blood supply. thepeptidelist.com files it under weight-loss.
How it works
Per thepeptidelist.com: targets prohibitin on the blood vessels supplying white adipose tissue, potentially disrupting blood supply to fat cells and triggering apoptosis (programmed cell death).
It’s a two-part molecule: a homing peptide that recognizes prohibitin-1 on the vasculature feeding white fat, fused to a pro-apoptotic sequence. Where it binds, it kills the local blood vessels, and the fat tissue they fed dies off. Powerful in concept — and the same blunt-instrument mechanism is the source of the safety problem.
What the research shows
- Preclinical fat-mass reduction in monkeys — obese rhesus monkeys lost substantial weight and fat mass in the foundational primate work.
- thepeptidelist.com grades it Anecdotal — 0 studies cited on the profile, 0 human trials. Its evidence summary: “No published clinical studies were found on PubMed for ADIPOTIDE. Evidence is limited to preclinical research or community reports.”
- No human trials.
Safety flag — the reason this one is graded RED
The primate trial that showed fat loss also showed a nephrotoxicity (kidney-damage) signal. That is not a footnote: it is the central fact about Adipotide. The mechanism that kills fat-tissue vasculature is not perfectly selective, and the kidney’s dense, high-flow vasculature appears to take collateral damage. Per the 0035 pass: “published nephrotoxicity signal in the primate trial… Safety red because of the preclinical nephrotoxicity signal.” (primary primate-study ).
The honest read (OHM doctrine: surface the safety data as information, not fear-bait, but surface it loudly because it’s real): Adipotide is a fascinating mechanism with a documented, mechanism-intrinsic toxicity signal in primates and zero human data. It belongs in the encyclopedia as the cautionary edge of the fat-loss-peptide map. We don’t moralize, and the final call is Rick’s — but the nephrotoxicity signal is a genuine, primary safety fact, not a marketing-fear overlay, and any content that mentions Adipotide should carry it plainly.
Real-world protocol
No human protocol — and given the primate nephrotoxicity signal and total absence of human data, none should be inferred. Encyclopedia-only.
Status
- Regulatory:
research_only, not FDA-approved, not eligible for compounding. - OHM grade: D / RED / provisional: “never recommended” in the source grading, driven by the preclinical nephrotoxicity signal.
- Alyve catalog: Not in the launch 15.
The Alyve story — and where the real fat-loss SKUs are
None of the five compounds in this cluster is in Alyve’s launch catalog, and that’s the right call for each: AOD-9604 and HGH Fragment 176-191 carry a negative human Phase 2; AICAR and SLU-PP-332 are preclinical-only (one WADA-banned); Adipotide carries a primate nephrotoxicity signal. This article is encyclopedia/authority content — the honest map of fat-loss peptides outside the GLP-1 class.
For readers who want a metabolic / fat-loss peptide Alyve actually sells, with a verified COA behind it, the relevant SKUs are:
- Retatrutide — the flagship. A triple GLP-1/GIP/glucagon agonist (not a single GLP-1) with the strongest human weight-loss data in the whole peptide space — a different evidence universe from anything in this cluster.
- Tesamorelin — an FDA-approved GHRH analog with documented visceral-fat reduction in human trials; the GH-axis route to fat loss done with a molecule that has real human data.
- MOTS-c — the mitochondrial-derived metabolic peptide; the legitimate “metabolic optimization” lane this cluster’s exercise-mimetics only gesture at preclinically.
Alyve’s launch catalog is US-manufactured, third-party COA-verified (Freedom Diagnostics, >99% purity, identity-confirmed) — which is exactly the difference between the verified-clean tier and the gray-market research-chemical vendors that carry the compounds in this cluster.
Use code OHM-15 for 15% off: Alyve’s pricing is very competitive, and buying 3 vials of any given peptide in one purchase gets you over 30% off retail. The cluster compounds above aren’t sold by Alyve, so OHM-15 applies only via the metabolic SKUs that are — a 3-vial block of Retatrutide, Tesamorelin, or MOTS-c crosses the bulk threshold at the highest discount tier.
Sources
- thepeptidelist.com directory profiles; primary source for mechanism, site evidence tier, regulatory status, and the cited PMIDs (all site-derived citations carry per KB doctrine).
- OHM tier/safety/goal grading for all five (AOD-9604 C/green; HGH Fragment 176-191 D; AICAR D; SLU-PP-332 D; Adipotide D/RED), including the AOD failed-Phase-2 note, the AICAR Salk/WADA note, and the Adipotide primate nephrotoxicity signal.
- one practitioner cheat sheet; notes AOD-9604 in the non-Alyve / future-expansion list (specific dosing row not captured in the Alyve-relevant extract).
Related: Retatrutide · MOTS-c · SS-31 (Elamipretide) · Tesamorelin · The 2026 GLP-1 pipeline — Dulaglutide, Liraglutide, Semaglutide, Tirzepatide, CagriSema, Mazdutide, MariTide, Pemvidutide, Petrelintide, VK2735, Orforglipron, Survodutide, Eloralintide, Retatrutide.
Sources & references
- thepeptidelist.com directory profiles; primary source for mechanism, site evidence tier, regulatory status, and the cited PMIDs (all site-derived citations carry per KB doctrine).
- OHM tier/safety/goal grading for all five (AOD-9604 C/green; HGH Fragment 176-191 D; AICAR D; SLU-PP-332 D; Adipotide D/RED), including the AOD failed-Phase-2 note, the AICAR Salk/WADA note, and the Adipotide primate nephrotoxicity signal.
- one practitioner cheat sheet; notes AOD-9604 in the non-Alyve / future-expansion list (specific dosing row not captured in the Alyve-relevant extract).
Related: Retatrutide · MOTS-c · SS-31 (Elamipretide) · Tesamorelin · The 2026 GLP-1 pipeline — Dulaglutide, Liraglutide, Semaglutide, Tirzepatide, CagriSema, Mazdutide, MariTide, Pemvidutide, Petrelintide, VK2735, Orforglipron, Survodutide, Eloralintide, Retatrutide.